Early Results from First-In-U.S. Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest Safety of Approach

Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients

Tmunity Raises $75 Million in Series B Financing to Advance Next-Generation T-Cell Therapies

Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma

Tmunity Announces Presentation at the Cantor Fitzgerald 2019 Global Healthcare Conference

Tmunity Announces Participation at Upcoming Investor Conferences

Be The Match BioTherapies® and Tmunity Announce Collaboration to Support Clinical Trials of Next-Generation Immunotherapies

Tmunity Announces June 2019 Investor Conference Schedule

Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers

Tmunity Announces Participation at Four Upcoming Investor Conferences

Tmunity Appoints Patrick Gray and Garry Nicholson to its Board of Directors as Independent Directors

Tmunity to Present at the 37th Annual J.P. Morgan Healthcare Conference

FierceBiotech names Tmunity as one of its “Fierce 15” Biotech Companies of 2018

Tmunity Names Moji James as General Counsel and Executive Vice President

Tmunity Names Graeme Bell as Chief Financial Officer and Executive Vice President

Tmunity Appoints Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President

Tmunity Raises Additional $35 Million in Series A Financing, Bringing Series A Total to $135 Million to Advance Next-Generation T Cell Therapies